Last updated: 2020.09.29
About the section
Integrative cancer genomics is a new section at the Research Department and was established in 2020. The research is mostly external financed though with from the Cancer Society, The Norwegian Research Council and EUs Horizon 2020.
The section administers two major biobanks, the NORCCAP biobank containing feces and blood collected from 1999-2001, and the CRC-biome biobank, which contains feces samples from the ongoing Bowel Cancer Screening in Norway trial.
To integrate data from population-based surveys, cancer screening, national registries, and clinical studies with omics analyses of related biological samples to understand cancer development and develop cancer biomarkers.
We will take advantage of our expertise in molecular biology, next-generation sequencing protocols, and other omics technologies, bioinformatics, high-performance computing, and machine learning methods. These will be combined with the use of unique biobank materials and data sources to discover how early molecular changes in non-invasive fluids/materials can predict cancer. Our current focus is genomics, transcriptomics, epigenomics, and microbiome analyses of fecal and blood samples. We are always looking for new, innovative partners and projects supporting our vision.
Epigenetics and Cancer
Raju SC, Viljakainen H, Figueiredo RAO, Neuvonen PJ, Eriksson JG, Weiderpass E, Rounge TB (2020)
Antimicrobial drug use in the first decade of life influences saliva microbiota diversity and composition
Microbiome, 8 (1), 121
DOI 10.1186/s40168-020-00893-y, PubMed 32825849